Light therapy trial aims to boost immune attack on pancreatic cancer
NCT ID NCT06381154
Summary
This study is testing a new combination treatment for pancreatic cancer that cannot be removed by surgery or has spread. The approach uses a light-activated drug injected into the tumor to help the patient's own immune system, boosted by an immunotherapy drug (pembrolizumab), better recognize and attack the cancer cells. All participants will also receive standard chemotherapy. The main goal is to see how many patients' tumors shrink in response to this three-part treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.